Literature DB >> 26470915

Role of Adaptor Protein Toll-Like Interleukin Domain Containing Adaptor Inducing Interferon β in Toll-Like Receptor 3- and 4-Mediated Regulation of Hepatic Drug Metabolizing Enzyme and Transporter Genes.

Pranav Shah1, Ozozoma Omoluabi1, Bhagavatula Moorthy1, Romi Ghose2.   

Abstract

The expressions and activities of hepatic drug-metabolizing enzymes and transporters (DMETs) are altered during infection and inflammation. Inflammatory responses in the liver are mediated primarily by Toll-like receptor (TLR)-signaling, which involves recruitment of Toll/interleukin (IL)-1 receptor (TIR) domain containing adaptor protein (TIRAP) and TIR domain containing adaptor inducing interferon (IFN)-β (TRIF) that eventually leads to induction of proinflammatory cytokines and mitogen-activated protein kinases (MAPKs). Lipopolysaccharide (LPS) activates the Gram-negative bacterial receptor TLR4 and polyinosinic:polycytidylic acid (polyI:C) activates the viral receptor TLR3. TLR4 signaling involves TIRAP and TRIF, whereas TRIF is the only adaptor protein involved in the TLR3 pathway. We have shown previously that LPS-mediated downregulation of DMETs is independent of TIRAP. To determine the role of TRIF, we treated TRIF(+/+) and TRIF(-/-) mice with LPS or polyI:C. LPS downregulated (∼40%-60%) Cyp3a11, Cyp2a4, Ugt1a1, Mrp2 mRNA levels, whereas polyI:C downregulated (∼30%-60%) Cyp3a11, Cyp2a4, Cyp1a2, Cyp2b10, Ugt1a1, Mrp2, and Mrp3 mRNA levels in TRIF(+/+) mice. This downregulation was not attenuated in TRIF(-/-) mice. Induction of cytokines by LPS was observed in both TRIF(+/+) and TRIF(-/-) mice. Cytokine induction was delayed in polyI:C-treated TRIF(-/-) mice, indicating that multiple mechanisms mediating polyI:C signaling exist. To assess the role of MAPKs, primary hepatocytes were pretreated with specific inhibitors before treatment with LPS/polyI:C. We found that only the c-jun-N-terminal kinase (JNK) inhibitor attenuated the down-regulation of DMETs. These results show that TRIF-independent pathways can be involved in the downregulation of DMETs through TLR4 and 3. JNK-dependent mechanisms likely mediate this downregulation.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26470915      PMCID: PMC4702015          DOI: 10.1124/dmd.115.066761

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  27 in total

1.  Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4.

Authors:  Masahiro Yamamoto; Shintaro Sato; Hiroaki Hemmi; Hideki Sanjo; Satoshi Uematsu; Tsuneyasu Kaisho; Katsuaki Hoshino; Osamu Takeuchi; Masaya Kobayashi; Takashi Fujita; Kiyoshi Takeda; Shizuo Akira
Journal:  Nature       Date:  2002-11-21       Impact factor: 49.962

2.  Viral infections activate types I and III interferon genes through a common mechanism.

Authors:  Kazuhide Onoguchi; Mitsutoshi Yoneyama; Azumi Takemura; Shizuo Akira; Tadatsugu Taniguchi; Hideo Namiki; Takashi Fujita
Journal:  J Biol Chem       Date:  2007-01-04       Impact factor: 5.157

3.  SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase.

Authors:  B L Bennett; D T Sasaki; B W Murray; E C O'Leary; S T Sakata; W Xu; J C Leisten; A Motiwala; S Pierce; Y Satoh; S S Bhagwat; A M Manning; D W Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

4.  The signal transduction pathways involved in hepatic cytochrome P450 regulation in the rat during a lipopolysaccharide-induced model of central nervous system inflammation.

Authors:  Dalya Abdulla; Kerry B Goralski; Elena Garcia Del Busto Cano; Kenneth W Renton
Journal:  Drug Metab Dispos       Date:  2005-07-08       Impact factor: 3.922

5.  IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction.

Authors:  Taro Kawai; Ken Takahashi; Shintaro Sato; Cevayir Coban; Himanshu Kumar; Hiroki Kato; Ken J Ishii; Osamu Takeuchi; Shizuo Akira
Journal:  Nat Immunol       Date:  2005-08-28       Impact factor: 25.606

Review 6.  Regulation of cytochromes P450 during inflammation and infection.

Authors:  E T Morgan
Journal:  Drug Metab Rev       Date:  1997-11       Impact factor: 4.518

7.  Role of constitutive androstane receptor in Toll-like receptor-mediated regulation of gene expression of hepatic drug-metabolizing enzymes and transporters.

Authors:  Pranav Shah; Tao Guo; David D Moore; Romi Ghose
Journal:  Drug Metab Dispos       Date:  2013-11-05       Impact factor: 3.922

8.  The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors.

Authors:  Tiffany Horng; Gregory M Barton; Richard A Flavell; Ruslan Medzhitov
Journal:  Nature       Date:  2002-11-21       Impact factor: 49.962

9.  Subcellular localization of Toll-like receptor 3 in human dendritic cells.

Authors:  Misako Matsumoto; Kenji Funami; Masako Tanabe; Hiroyuki Oshiumi; Masashi Shingai; Yoshiyuki Seto; Akitsugu Yamamoto; Tsukasa Seya
Journal:  J Immunol       Date:  2003-09-15       Impact factor: 5.422

10.  Endotoxin leads to rapid subcellular re-localization of hepatic RXRalpha: A novel mechanism for reduced hepatic gene expression in inflammation.

Authors:  Romi Ghose; Tracy L Zimmerman; Sundararajah Thevananther; Saul J Karpen
Journal:  Nucl Recept       Date:  2004-08-16
View more
  6 in total

1.  Regulation of human placental drug transporters in HCV infection and their influence on direct acting antiviral medications.

Authors:  Emily Pfeifer; Jessica Parrott; Gene T Lee; Ericka Domalakes; Helen Zhou; Lily He; Clifford W Mason
Journal:  Placenta       Date:  2018-07-10       Impact factor: 3.481

2.  Physiological Regulation of Drug Metabolism and Transport: Pregnancy, Microbiome, Inflammation, Infection, and Fasting.

Authors:  Edward T Morgan; Joseph L Dempsey; Sylvie M Mimche; Tracey J Lamb; Supriya Kulkarni; Julia Yue Cui; Hyunyoung Jeong; Angela L Slitt
Journal:  Drug Metab Dispos       Date:  2018-03-07       Impact factor: 3.922

Review 3.  Regulation of drug-metabolizing enzymes in infectious and inflammatory disease: implications for biologics-small molecule drug interactions.

Authors:  Pankajini Mallick; Guncha Taneja; Bhagavatula Moorthy; Romi Ghose
Journal:  Expert Opin Drug Metab Toxicol       Date:  2017-02-22       Impact factor: 4.481

4.  Neratinib causes non-recoverable gut injury and reduces intestinal cytochrome P450 3A enzyme in mice.

Authors:  Gabriel Tao; Fatima Dagher; Romi Ghose
Journal:  Toxicol Res (Camb)       Date:  2022-01-18       Impact factor: 3.524

Review 5.  Distinct Effects of Inflammation on Cytochrome P450 Regulation and Drug Metabolism: Lessons from Experimental Models and a Potential Role for Pharmacogenetics.

Authors:  Laura M de Jong; Wim Jiskoot; Jesse J Swen; Martijn L Manson
Journal:  Genes (Basel)       Date:  2020-12-16       Impact factor: 4.096

Review 6.  Potential role of drug metabolizing enzymes in chemotherapy-induced gastrointestinal toxicity and hepatotoxicity.

Authors:  Gabriel Tao; Junqing Huang; Bhagavatula Moorthy; Cathryn Wang; Ming Hu; Song Gao; Romi Ghose
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-09-02       Impact factor: 4.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.